Amgen, AstraZeneca Report Full Positive Phase 3 Tezepelumab Results

By Colin Kellaher

Amgen Inc. and AstraZeneca PLC on Friday reported full positive results from a pivotal Phase 3 trial of tezepelumab, a potential treatment for patients with severe, uncontrolled asthma.

The companies said the study, dubbed "Navigator," showed superiority versus placebo across every primary and key secondary endpoint, with a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate in severe, uncontrolled asthma patients.

Amgen and AstraZeneca said tezepelumab is the only biologic to consistently and significantly reduce the exacerbation rate in a broad population of severe asthma patients, and they noted that results from the study will form the basis of regulatory filings for the drug.

U.K. pharmaceutical giant AstraZeneca and Amgen, a Thousand Oaks, Calif., biotechnology company, agreed in 2012 to collaborate on tezepelumab.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 26, 2021 09:59 ET (14:59 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024